NL-OMON45469撤回不适用
Adoptive TIL therapy plus anti-PD1 in metastatic melanoma <br> - ACTME
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Age * 18 years.
- •2. Histologically or cytologically proven metastatic skin melanoma.
- •3. Melanoma must be at one of the following AJCC 2009 stages:
- •-Unresectable (or residual) regional metastatic melanoma, i.e. in terms of AJCC 2009 classification unresectable stage III melanoma, or
- •-Stage IV melanoma, i.e. distant metastatic disease (any T, any N, M1a, M1b or M1c), and normal LDH.
- •4. Patients with brain metastases have to be neurologically stable for at least 2 months and should not use dexamethasone.
- •5. Presence of measurable progressive disease according to RECIST version 1.1.
- •6. Expected survival of at least 3 months.
- •7. WHO performance status *1.
- •8. Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified :
- •Lab Parameter Range
- •Hemoglobin * 6,0 mmol/l
- •Granulocytes * 1,500/µl
- •Lymphocytes * 700/µl
- •Platelets * 100,000/µl
- •Creatinine clearance * 60 min/ml
- •Serum bilirubin * 40 mol/l
- •ASAT and ALAT * 5 x the normal upper limit
- •LDH * 2 x the normal upper limit
- •9. Viral tests:
- •-Negative for HIV type 1/2, HTLV and TPHA
- •-No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum
- •-No antibodies against HCV (hepatitis C virus) in the serum
- •10. Able and willing to give valid written informed consent.
- •11. Prior treatment is allowed, including anti-PD1 treatment, but systemic therapy must have been discontinued for at least four weeks before study entry. Radiotherapy and targeted therapy should be discontinued for at least two weeks before study entry.
排除标准
- •1. Patients with brain metastases who are neurologically unstable and/or on use of dexamethasone.
- •2. Clinically significant heart disease (NYHA Class III or IV).
- •3. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.
- •4. Active immunodeficiency disease or autoimmune disease requiring immune suppressive drugs. Vitiligo is not an exclusion criterion.
- •5. Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical carcinoma.
- •6. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
- •7. Lack of availability for follow-up assessments.
- •8. Pregnancy or breastfeeding.
研究者
相似试验
撤回
不适用
Adoptive TIL therapy plus anti-PD1 in metastatic melanomamelanomaskin cancerNL-OMON44437eids Universitair Medisch Centrum25
进行中（未招募）
1 期
A phase I/II study with adoptive TIL-therapy in combination with anti-PD1 (Nivolumab) in patients with metastatic skin melanomaEUCTR2016-004426-41-NLeiden University Medical Center
招募中
1 期
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILSMetastatic Triple-Negative Breast CarcinomaNCT05451784Fundacio Clinic Barcelona20
尚未招募
不适用
Adoptive TIL therapy in combination with chemoimmunotherapy in advanced NSCLC patients10029107non-small cell lung cancerNL-OMON53375eids Universitair Medisch Centrum15
招募中
3 期
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal CancerRectal NeoplasmsNCT06017583Yong Zhang,MD48